rts logo

Amylyx Pharmaceuticals Inc (AMLX) Stock Could Soon Reward Patient Investors

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) is -88.04% lower on its value in year-to-date trading and has touched a low of $1.65 and a high of $26.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AMLX stock was last observed hovering at around $1.77 in the last trading session, with the day’s loss setting it -0.01%.

Currently trading at $1.76, the stock is -0.52% and -12.31% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.35 million and changing -0.56% at the moment leaves the stock -85.36% off its SMA200. AMLX registered -93.30% loss for a year compared to 6-month loss of -87.62%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a -6.88% gain in the last 1 month and extending the period to 3 months gives it a -53.68%, and is 3.53% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.30% over the week and 5.37% over the month.

Amylyx Pharmaceuticals Inc (AMLX) has around 384 employees, a market worth around $119.70M and $398.00M in sales. Profit margin for the company is -17.86%. Distance from 52-week low is 6.67% and -93.32% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.82%).

with sales reaching $10.66M over the same period.The EPS is expected to shrink by -508.33% this year, but quarterly earnings will post -74.50% year-over-year. Quarterly sales are estimated to shrink -89.10% in year-over-year returns.

Amylyx Pharmaceuticals Inc (AMLX) Top Institutional Holders

The shares outstanding are 67.71M, and float is at 45.89M with Short Float at 17.41%.

Amylyx Pharmaceuticals Inc (AMLX) Insider Activity

The most recent transaction is an insider purchase by Quimi Daphne,the company’sDirector. SEC filings show that Quimi Daphne bought 2,250 shares of the company’s common stock on May 15 ’24 at a price of $1.89 per share for a total of $4252.0. Following the purchase, the insider now owns 5000.0 shares.

Amylyx Pharmaceuticals Inc disclosed in a document filed with the SEC on May 15 ’24 that Mazzariello Gina (Chief Legal Officer) sold a total of 10,455 shares of the company’s common stock. The trade occurred on May 15 ’24 and was made at $1.88 per share for $19654.0. Following the transaction, the insider now directly holds 0.15 million shares of the AMLX stock.

Still, SEC filings show that on May 14 ’24, Quimi Daphne (Director) acquired 2,750 shares at an average price of $1.89 for $5184.0. The insider now directly holds 2,750 shares of Amylyx Pharmaceuticals Inc (AMLX).

Related Posts